Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
BackgroundHemangioblastoma (HB) is a rare and highly vascularized tumor that originates from the central nervous system as well as other part of the body. They can appear sporadically or as part of von Hippel–Lindau (VHL) disease, a rare hereditary cancer syndrome. Although surgery can cure the majo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.859157/full |
| _version_ | 1828491141525274624 |
|---|---|
| author | Nan Jin Nan Jin Chunxiao Sun Yijia Hua Xinyu Wu Wei Li Yongmei Yin Yongmei Yin |
| author_facet | Nan Jin Nan Jin Chunxiao Sun Yijia Hua Xinyu Wu Wei Li Yongmei Yin Yongmei Yin |
| author_sort | Nan Jin |
| collection | DOAJ |
| description | BackgroundHemangioblastoma (HB) is a rare and highly vascularized tumor that originates from the central nervous system as well as other part of the body. They can appear sporadically or as part of von Hippel–Lindau (VHL) disease, a rare hereditary cancer syndrome. Although surgery can cure the majority of HBs, the disease shows a treatment-refractory challenge upon recurrence. HBs express a high amount of vascular endothelial growth factor (VEGF) which is responsible for angiogenesis and subsequently tumor progression. Anti-angiogenic treatment like bevacizumab has showed effect on HB, so we hypothesized that anlotinib could trigger HB regression via its inhibitory effect on VEGF.Case PresentationWe will share our experience in treating a 62-year-old woman with multiple recurrent lumbar and sacral cord HBs. She was treated with anlotinib (8mg qd d1-14, q3w) for three months and her follow up radiological examination demonstrated marked tumor regression which was evaluated as having partial response pursuant to RECIST 1.1 system. She is currently still receiving treatment of anlotinib orally and the lesions continuously reduced.ConclusionWe have reported that anlotinib can cause significant radiographic response in a patient with multiple recurrent lumbar and sacral cord HBs for the first time. This might enable a novel therapeutic approach for patients with multiple recurrent HB or those with multiple lesions such as in VHL disease which are difficult to resect surgically. |
| first_indexed | 2024-12-11T10:57:04Z |
| format | Article |
| id | doaj.art-1b110430a71842fc9a860eae0d4872c7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T10:57:04Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1b110430a71842fc9a860eae0d4872c72022-12-22T01:10:00ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.859157859157Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case ReportNan Jin0Nan Jin1Chunxiao Sun2Yijia Hua3Xinyu Wu4Wei Li5Yongmei Yin6Yongmei Yin7Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaThe First Clinical College of Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaJiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, ChinaBackgroundHemangioblastoma (HB) is a rare and highly vascularized tumor that originates from the central nervous system as well as other part of the body. They can appear sporadically or as part of von Hippel–Lindau (VHL) disease, a rare hereditary cancer syndrome. Although surgery can cure the majority of HBs, the disease shows a treatment-refractory challenge upon recurrence. HBs express a high amount of vascular endothelial growth factor (VEGF) which is responsible for angiogenesis and subsequently tumor progression. Anti-angiogenic treatment like bevacizumab has showed effect on HB, so we hypothesized that anlotinib could trigger HB regression via its inhibitory effect on VEGF.Case PresentationWe will share our experience in treating a 62-year-old woman with multiple recurrent lumbar and sacral cord HBs. She was treated with anlotinib (8mg qd d1-14, q3w) for three months and her follow up radiological examination demonstrated marked tumor regression which was evaluated as having partial response pursuant to RECIST 1.1 system. She is currently still receiving treatment of anlotinib orally and the lesions continuously reduced.ConclusionWe have reported that anlotinib can cause significant radiographic response in a patient with multiple recurrent lumbar and sacral cord HBs for the first time. This might enable a novel therapeutic approach for patients with multiple recurrent HB or those with multiple lesions such as in VHL disease which are difficult to resect surgically.https://www.frontiersin.org/articles/10.3389/fonc.2022.859157/fullanlotinibhemangioblastomaanti-angiogenesiscase reporttyrosine kinase inhibitor (TKI) |
| spellingShingle | Nan Jin Nan Jin Chunxiao Sun Yijia Hua Xinyu Wu Wei Li Yongmei Yin Yongmei Yin Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report Frontiers in Oncology anlotinib hemangioblastoma anti-angiogenesis case report tyrosine kinase inhibitor (TKI) |
| title | Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report |
| title_full | Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report |
| title_fullStr | Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report |
| title_full_unstemmed | Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report |
| title_short | Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report |
| title_sort | anlotinib for the treatment of multiple recurrent lumbar and sacral cord hemangioblastomas a case report |
| topic | anlotinib hemangioblastoma anti-angiogenesis case report tyrosine kinase inhibitor (TKI) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.859157/full |
| work_keys_str_mv | AT nanjin anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT nanjin anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT chunxiaosun anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT yijiahua anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT xinyuwu anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT weili anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT yongmeiyin anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport AT yongmeiyin anlotinibforthetreatmentofmultiplerecurrentlumbarandsacralcordhemangioblastomasacasereport |